1-5 of 5
Martin Page
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy P.S. Perera, Eleonora Jovcheva, Laurence Mevellec, Jorge Vialard, Desiree De Lange, Tinne Verhulst, Caroline Paulussen, Kelly Van De Ven, Peter King, Eddy Freyne, David C. Rees, Matthew Squires, Gordon Saxty, Martin Page, Christopher W. Murray, Ron Gilissen, George Ward, Neil T. Thompson, David R. Newell, Na Cheng, Liang Xie, Jennifer Yang, Suso J. Platero, Jayaprakash D. Karkera, Christopher Moy, Patrick Angibaud, Sylvie Laquerre, Matthew V. Lorenzi
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (6): 1010–1020.
https://doi.org/10.1158/1535-7163.MCT-16-0589
Published: 01 June 2017
View article titled, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Open the PDF for Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor in another window
Includes: Supplementary data
Journal Articles

Abstract A142: In vivo response and molecular characterization of a Caucasian NSCLC squamous cell carcinoma PDX sensitive to FGFR inhibitor.

Andrew J. McKenzie, Aaron N. Cranston, Nektaria Papadopoulou, Simon Jiang, Jane Wrigley, Yinfei Yin, Henry Li, Martin Page, Rajendra Kumari
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A142.
https://doi.org/10.1158/1535-7163.TARG-13-A142
Published: 01 November 2013
View article titled, Abstract A142: <em>In vivo</em> response and molecular characterization of a Caucasian NSCLC squamous cell carcinoma PDX sensitive to FGFR inhibitor.
Journal Articles

Abstract A145: In vivo and in vitro generation and characterization of EGFR TKI resistance in a patient-derived and a cell line-derived xenograft model of NSCLC with activating EGFR mutations.

Andrew J. McKenzie, Aaron N. Cranston, Nektaria Papadopoulou, Simon Jiang, Jane Wrigley, Yinfei Yin, Henry Li, Martin Page, Rajendra Kumari
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A145.
https://doi.org/10.1158/1535-7163.TARG-13-A145
Published: 01 November 2013
View article titled, Abstract A145: <em>In vivo</em> and <em>in vitro</em> generation and characterization of EGFR TKI resistance in a patient-derived and a cell line-derived xenograft model of NSCLC with activating EGFR mutations.
Journal Articles

Abstract B111: Differential expression of c‐Met/HGF axis and epithelial‐mesenchymal transition (EMT)‐related gene markers between primary colorectal carcinomas and liver metastases in primary tissue, isolated cell types and in vivo

Richard H. Argent, Philip Clarke, Dileep N. Lobo, Kate Shepherd, Peter King, Brett Hall, Martin Page, Rajendra Kumari, Anna Grabowska, Susan A. Watson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B111.
https://doi.org/10.1158/1535-7163.TARG-09-B111
Published: 10 December 2009
View article titled, Abstract B111: Differential expression of c‐Met/HGF axis and epithelial‐mesenchymal transition (EMT)‐related gene markers between primary colorectal carcinomas and liver metastases in primary tissue, isolated cell types and <em>in vivo</em>
Journal Articles

Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout

Matthias Versele, Willem Talloen, Cindy Rockx, Tamara Geerts, Boud Janssen, Tom Lavrijssen, Peter King, Hinrich W.H. Göhlmann, Martin Page, Tim Perera
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1846–1855.
https://doi.org/10.1158/1535-7163.MCT-08-1029
Published: 14 July 2009
View article titled, Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout
Open the PDF for Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout in another window
Includes: Supplementary data